Wissen Research：到2031年，尿液分析市场规模将达到59亿美元，随着自动化和肾脏疾病筛查的扩展，年复合增长率为7%-动脉网

Urinalysis Market to Reach US$ 5.9 Bn by 2031, Growing at 7% CAGR as Automation and Kidney Disease Screening Expand: Wissen Research

CISION 等信源发布 2026-10-20 23:00



可切换为仅中文







SHERIDAN, Wyo.

谢里登，怀俄明州

，

Oct. 20, 2026

2026年10月20日

/PRNewswire/ -- The global

/美通社/ -- 全球

urinalysis market

尿液分析市场

is valued at USD 4.2 billion in 2026 and is projected to reach USD 5.9 billion by 2031, growing at a CAGR of 7% over the forecast period (2026-2031), according to a new study by Wissen Research.

根据Wissen Research的一项新研究，该市场在2026年的估值为42亿美元，预计到2031年将达到59亿美元，在预测期（2026-2031年）内的复合年增长率（CAGR）为7%。

Urinalysis is one of the most routine tests in medicine. Hospitals, clinics and laboratories use it to screen for urinary tract infections, kidney disorders and diabetes-related complications, and to monitor patients over time. The market covers reagent strips, reagents, automated and point-of-care analyzers, and the consumables that go with them.

尿常规检查是医学中最常规的检验项目之一。医院、诊所和实验室利用它来筛查尿路感染、肾脏疾病以及糖尿病相关并发症，并对患者进行长期监测。该市场涵盖试纸条、试剂、自动化及即时检测分析仪，以及与之配套的耗材。

Growth is being shaped by heavier lab workloads, a sharper focus on early kidney disease detection, and a steady move toward automated, connected testing..

增长正受到更繁重的实验室工作量、对早期肾病检测的更强烈关注，以及向自动化、联网检测的稳步转变等因素的塑造。

Get a Free Sample of This Report to Explore Key Findings and Data:

获取本报告免费样本，探索关键发现与数据：

https://www.wissenresearch.com/request-a-sample/?report=urinalysis-market

From Manual Microscopy to Automated, Connected Workflows

从手动显微镜检查到自动化、互联的工作流程

Laboratories are replacing manual steps with systems that combine urine chemistry and particle analysis in a single workflow. The aim is straightforward: fewer repetitive manual reviews, more consistent results and the capacity to handle growing test volumes. Digital imaging and automated particle classification are doing more of the sediment work, and analyzers increasingly link to laboratory information systems and electronic medical records..

实验室正采用将尿液化学分析与颗粒分析整合于单一工作流程的系统，以取代人工操作步骤。其目标明确：减少重复性的人工镜检，提高结果的一致性，并提升应对日益增长的检测量的能力。数字成像和自动颗粒分类技术承担了更多的尿沉渣分析工作，且分析仪正越来越多地与实验室信息系统及电子病历实现对接。

The workload behind this shift is large. Beckman Coulter Diagnostics notes that roughly one in three U.S. emergency department visits includes a urine test, and nearly half of hospital admissions involve urinalysis. On July 23, 2026, the company launched its DxU 1800 System in the United States, pairing a chemistry analyzer that handles up to 300 samples per hour with a microscopy analyzer.

这一转变背后的工作量巨大。贝克曼库尔特诊断公司指出，在美国，大约每三次急诊就诊中就有一次包含尿液检测，近一半的住院患者涉及尿液化验。2026年7月23日，该公司在美国推出了DxU 1800系统，将一台每小时可处理多达300个样本的生化分析仪与一台显微镜分析仪相结合。

According to the company, the integrated system brings manual microscopic review below 3%..

据该公司称，该集成系统将人工显微镜复检率降至3%以下。

Request a Customized Version of This Report:

申请本报告的定制版本：

https://www.wissenresearch.com/request-customization/?report=urinalysis-market

Compact Systems Open the Market Beyond Large Labs

紧凑型系统打开大型实验室之外的市场

Automation is no longer limited to high-volume hospital laboratories. Sysmex Corporation's UF-1500 particle analyzer runs up to 60 samples per hour and is about 30% smaller than the company's UF-5000, which suits laboratories with limited space. On the connectivity side, Siemens Healthineers offers the CLINITEK Status Connect system, which links point-of-care urinalysis devices to laboratory and hospital information systems and electronic records using HL7 and POCT1-A2 protocols..

自动化不再局限于高通量的医院实验室。希森美康（Sysmex Corporation）的UF-1500颗粒分析仪每小时可处理多达60个样本，体积比该公司的UF-5000小约30%，适合空间有限的实验室。在连接性方面，西门子医疗（Siemens Healthineers）提供CLINITEK Status Connect系统，该系统利用HL7和POCT1-A2协议，将即时检验尿液分析设备与实验室信息系统、医院信息系统以及电子病历相连接。

The report adds a caution here: these specifications show how the technology is developing, but they are not independent measures of how widely it has been adopted.

报告在此提出警示：这些规格指标展示了技术的发展态势，但并不能独立反映其普及程度。

What's Fueling Growth in the Urinalysis Market

尿液分析市场增长的驱动因素

Kidney Disease Screening:

肾脏疾病筛查：

Urine albumin and protein testing is central to detecting kidney damage, particularly in people with diabetes or hypertension.

尿白蛋白和蛋白质检测是发现肾损伤的关键，尤其对于患有糖尿病或高血压的人群。

Infection Assessment:

感染评估：

Reagent strips and automated sediment analysis help clinicians quickly check for leukocytes, nitrites and blood when a urinary tract infection is suspected.

当怀疑存在尿路感染时，试剂条和自动沉渣分析有助于临床医生快速检测白细胞、亚硝酸盐和血液。

Laboratory Automation:

实验室自动化：

Large laboratories are adopting automated analyzers to standardize results, avoid manual microscopy and manage growing routine workloads.

大型实验室正在采用自动化分析仪，以标准化检测结果、避免人工显微镜检查，并应对日益增长的常规工作量。

Point-of-Care Testing:

即时检测：

Compact analyzers let clinics and emergency settings test on site rather than waiting on a central laboratory.

紧凑型分析仪使诊所和急诊环境能够进行现场检测，而无需等待中心实验室的结果。

Hospital Testing Volumes:

医院检测量：

Urine tests are used to evaluate infection and renal function in pre-operative and in-patient care, which keeps consumables demand steady.

尿液检测用于评估术前和住院护理中的感染情况与肾功能，从而保持对耗材需求的稳定。

Kidney Disease Is Creating a Clear Testing Opportunity

肾病正在创造明确的检测机遇

The World Health Organization reported on April 20, 2026 that an estimated 674 million people worldwide have chronic kidney disease, and it identifies urine albumin testing as an important tool for early detection. The American Diabetes Association recommends assessing both urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate in all people with type 2 diabetes.

世界卫生组织于2026年4月20日报告称，全球约有6.74亿人患有慢性肾脏病，并指出尿白蛋白检测是早期发现的重要工具。美国糖尿病协会建议对所有2型糖尿病患者评估尿白蛋白与肌酐比值（UACR）和估算肾小球滤过率。

In May 2025, the National Kidney Foundation reported that an expert workshop recommended urinary albumin measurement as the preferred approach to screening and monitoring high-risk adults, and noted that the test remains underused because of limited awareness and cost..

2025年5月，美国国家肾脏基金会报告称，一次专家研讨会建议将尿白蛋白测量作为筛查和监测高危成年人的首选方法，并指出由于认知度有限和成本问题，该检测仍未得到充分利用。

For manufacturers, this points toward quantitative albumin and creatinine assays, UACR-capable analyzers and affordable systems for diabetes clinics and primary care. The report is careful to note that the opportunity rests on clinical guidelines and disease burden, not on the assumption that every person with kidney disease needs the same urine test..

对于制造商而言，这意味着应面向糖尿病诊所和初级保健机构，提供定量白蛋白和肌酐检测、具备尿白蛋白/肌酐比值（UACR）检测能力的分析仪以及经济实惠的系统。报告谨慎地指出，这一市场机会源于临床指南和疾病负担，而非基于“每位肾病患者都需要进行相同的尿液检测”的假设。

Challenges Facing the Urinalysis Market

尿液分析市场面临的挑战

Accuracy and follow-up remain the biggest issues. Standard reagent strips give qualitative or semi-quantitative readings that can be thrown off by urine concentration, sample handling and interference, and a urinalysis alone is often not enough for a conclusive diagnosis. A study published in

准确性和随访仍然是最大的问题。标准试纸条提供的定性或半定量读数可能受到尿液浓度、样本处理和干扰因素的影响，仅凭尿常规检查往往不足以做出确诊。一项发表在

Urology

泌尿外科学

in September 2025 covered 37,300 patients across 109 U.S. health systems who had positive dipstick results. It found that 31% did not receive confirmatory microscopic urinalysis, and that 7.5% of patients tested by dipstick without microscopy went on to imaging or cystoscopy.

2025年9月的一项研究涵盖了美国109个医疗系统中的37,300名试纸检测结果为阳性的患者。研究发现，31%的患者未接受确认性显微镜尿检，而在仅通过试纸检测而未进行显微镜检查的患者中，有7.5%随后接受了影像学检查或膀胱镜检查。

Cost is the second barrier. Automated analyzers require upfront investment, maintenance, staff training and a reliable supply of reagents, which can be difficult for smaller facilities. Manufacturers must also meet regulatory requirements and demonstrate that their systems perform as claimed.

成本是第二道障碍。自动化分析仪需要前期投资、维护、人员培训以及稳定的试剂供应，这对小型机构来说可能难以承受。制造商还必须满足监管要求，并证明其系统性能符合宣称的标准。

Recent Strategic Developments in the Urinalysis Market

尿液分析市场的近期战略发展

In July 2026

2026年7月

, Beckman Coulter Diagnostics of the United States launched the DxU 1800, a fully automated urinalysis system that integrates urine chemistry and microscopy. The company reports that it processes up to 300 samples per hour and reduces manual microscopic review to below 3%.

美国贝克曼库尔特诊断公司推出了DxU 1800，这是一款集成尿液化学分析和显微镜检查的全自动尿液分析系统。该公司报告称，该系统每小时可处理多达300个样本，并将人工显微镜复检率降低至3%以下。

In March 2026

2026年3月

, Siemens Healthineers AG of Germany expanded access to point-of-care urinalysis with its Atellica LumIQ Analyser, introduced on March 25. Manufactured in Sudbury, United Kingdom, the analyser automates reagent-strip interpretation, supports urine and hCG pregnancy testing, and enables connected near-patient testing to support earlier kidney disease detection..

德国西门子医疗股份公司（Siemens Healthineers AG）于3月25日推出了Atellica LumIQ分析仪，扩大了即时尿液分析的可及性。该分析仪在英国萨德伯里制造，可自动判读试纸条结果，支持尿液检测和hCG妊娠试验，并通过联网的近患者检测功能，助力更早发现肾脏疾病。

Both launches reflect a market competing on throughput, workflow integration and connectivity.

两次发布均反映出一个在吞吐量、工作流集成和连接性方面展开竞争的市场。

Key Insights from Urinalysis Market Analysis

尿液分析市场分析的关键洞察

Consumables

消耗品

held a leading position by product type in 2025. Reagent strips, liquid reagents, calibrators and quality-control materials are used repeatedly alongside installed analyzers, which creates recurring demand. Sysmex Corporation reported urinalysis sales of JPY 40.838 billion in fiscal 2025, up from JPY 39.031 billion in fiscal 2024..

2025年按产品类型计占据领先地位。试纸条、液体试剂、校准品和质控材料需与已安装的分析仪重复配套使用，从而产生持续性需求。希森美康株式会社（Sysmex Corporation）报告显示，其2025财年尿液分析销售额为408.38亿日元，较2024财年的390.31亿日元有所增长。

Biochemical tests

生化测试

held a leading position by test type in 2025, supported by routine strip-based screening for glucose, protein, blood, ketones, nitrites and pH.

2025年，凭借针对葡萄糖、蛋白质、血液、酮体、亚硝酸盐和pH值的常规试纸条筛查，按检测类型计占据了领先地位。

North America

北美

held a leading regional position in 2025, backed by extensive laboratory infrastructure. The CDC reported in November 2025 that healthcare professionals order more than 14 billion laboratory tests a year in the United States, and the National Kidney Foundation estimates more than 35 million U.S. adults have chronic kidney disease..

2025年，凭借广泛的实验室基础设施，该地区保持了领先地位。美国疾病控制与预防中心（CDC）在2025年11月报告称，美国医疗保健专业人员每年开具的实验室检测订单超过140亿份；美国国家肾脏基金会估计，美国有超过3,500万成年人患有慢性肾脏病。

Asia Pacific

亚太地区

is the fastest-growing region.

是增长最快的地区。

The market is moderately consolidated at the advanced instrument level, where established diagnostics companies compete on automated analyzers, integrated platforms and laboratory relationships. It remains fragmented across reagent strips, consumables, point-of-care devices and regional manufacturers..

在高端仪器层面，市场呈现中度整合态势，成熟的诊断公司围绕自动化分析仪、一体化平台以及实验室合作关系展开竞争。而在试剂条、耗材、即时检测设备以及区域性制造商领域，市场依然分散。

Key Players in the Urinalysis Market

尿液分析市场的主要参与者

Leading companies are focusing on automated diagnostic systems, urine chemistry and sediment analysis, digital imaging, product innovation and expansion across laboratories, hospitals, clinics and point-of-care settings.

领先企业正专注于自动化诊断系统、尿液化学与沉渣分析、数字成像、产品创新，并在实验室、医院、诊所及即时检测场景中拓展业务。

Company Name

公司名称

Key Focus Area

重点聚焦领域

Siemens Healthineers AG

西门子医疗股份公司

Laboratory and point-of-care urinalysis, including the CLINITEK Novus chemistry analyzer, connected CLINITEK Status Connect and the Atellica LumIQ Analyser.

实验室及即时检验尿液分析，包括 CLINITEK Novus 化学分析仪、联网的 CLINITEK Status Connect 以及 Atellica LumIQ 分析仪。

F. Hoffmann-La Roche Ltd

F. 霍夫曼-拉罗氏有限公司

Established diagnostics portfolio serving laboratory urinalysis.

成熟的诊断产品组合，服务于实验室尿液分析。

Sysmex Corporation

希森美康株式会社

Modular laboratory systems, automated particle analyzers such as the UF-1500, and digital imaging with the UD-10.

模块化实验室系统、UF-1500等自动化颗粒分析仪，以及UD-10数字成像系统。

Beckman Coulter, Inc.

贝克曼库尔特公司

Integrated chemistry-and-microscopy automation through the DxU 1800 System.

通过DxU 1800系统实现化学与显微技术的集成自动化。

ARKRAY, Inc.

爱科来株式会社

Urinalysis diagnostics for laboratories and clinical settings.

用于实验室和临床环境的尿液分析诊断。

View Pricing & License Options — Unlock Full Market Sizing & Competitive Benchmarking:

查看定价与许可选项 — 解锁完整的市场规模估算与竞争基准分析：

https://www.wissenresearch.com/market-research-reports-pricings/urinalysis-market

Regional Analysis and Growth Opportunities

区域分析与增长机遇

North America led the market in 2025, helped by the scale of its laboratory network. The CDC reports approximately 266,000 CLIA-certified laboratories operating across the United States, and regulators continue to clear new urine-testing products, including Healgen Scientific's URS Test Strips in December 2025..

2025年，北美凭借其实验室网络的规模优势引领市场。美国疾病控制与预防中心（CDC）报告显示，全美约有266,000家获得临床实验室改进修正案（CLIA）认证的实验室在运营，且监管机构持续批准新的尿液检测产品，其中包括2025年12月获批的Healgen Scientific公司URS试纸条。

Asia Pacific is expected to grow the fastest as access to primary care improves and the need to monitor chronic conditions rises. Manufacturers see opportunity in India, China, Indonesia and Thailand, where affordable automated systems and local laboratory networks are expanding. The report points to the World Health Organization's 2026 report on diabetes treatment in Southeast Asia, which documents stronger diabetes care systems across several countries in the region and supports earlier diagnosis.

随着初级保健可及性的改善以及慢性病监测需求的上升，亚太地区预计将实现最快增长。制造商在印度、中国、印度尼西亚和泰国看到了机遇，这些国家正在扩展负担得起的自动化系统和本地实验室网络。报告指出，世界卫生组织发布的《2026年东南亚糖尿病治疗报告》记录了该地区多个国家糖尿病护理体系的加强，并支持早期诊断。

Europe, Latin America and the Middle East & Africa complete the report's regional coverage..

欧洲、拉丁美洲以及中东和非洲地区完善了本报告的区域覆盖范围。

Market Segmentation Snapshot

市场细分概览

The global urinalysis market is segmented across product type, test type, application type, end user type and region:

全球尿液分析市场按产品类型、检测类型、应用类型、终端用户类型和地区进行细分：

By Product Type:

按产品类型：

Consumables (reagent strips, reagents and related materials)

耗材（试剂条、试剂及相关材料）

Instruments (integrated, sediment and biochemical urine analyzers)

仪器（集成式、沉渣和生化尿液分析仪）

By Test Type:

按测试类型：

Biochemical Tests

生化测试

Microscopic and Sediment Tests

显微镜检查与沉积物检测

Pregnancy and Fertility Tests

妊娠与生育力检测

Other Tests

其他测试

By Application Type:

按应用类型：

Urinary Tract Infection

尿路感染

Kidney Disease

肾病

Diabetes

糖尿病

Liver Disease

肝病

Pregnancy and Fertility

妊娠与生育

Other Applications

其他应用

By End User Type:

按最终用户类型：

Diagnostic Laboratories

诊断实验室

Hospitals and Clinics

医院与诊所

Home-Care Settings

居家护理环境

Research Laboratories and Institutes

研究实验室与研究所

By Region:

按地区：

North America

北美

Europe

欧洲

Asia-Pacific

亚太地区

Latin America

拉丁美洲

Middle East & Africa

中东与非洲

Frequently Asked Questions

常见问题

Q: What is the size of the urinalysis market?

问：尿液分析市场的规模有多大？

A: The global urinalysis market is estimated at USD 4.2 billion in 2026 and is projected to reach USD 5.9 billion by 2031.

A：预计2026年全球尿液分析市场规模为42亿美元，到2031年有望达到59亿美元。

Q: What is the growth rate of the urinalysis market?

问：尿液分析市场的增长率是多少？

A: The market is projected to grow at a CAGR of 7% between 2026 and 2031.

A：预计该市场在2026年至2031年期间将以7%的复合年增长率增长。

Q: What is urinalysis used for?

问：尿液分析用于什么目的？

A: Urinalysis analyzes urine samples to help detect, diagnose and monitor urinary tract infections, kidney disorders, diabetes and other conditions. It is also used for general health checks and pregnancy testing.

A：尿液分析通过对尿样进行检测，有助于发现、诊断和监测尿路感染、肾脏疾病、糖尿病及其他病症。它也被用于常规健康检查和妊娠测试。

Q: Which product type leads the urinalysis market?

问：哪种产品类型在尿液分析市场中占据主导地位？

A: Consumables held a leading position by product type in 2025, supported by recurring demand for reagent strips, reagents, calibrators and quality-control materials.

A：2025年，按产品类型划分，耗材占据领先地位，这得益于对试剂条、试剂、校准品和质控材料的持续需求。

Q: Which test type leads the urinalysis market?

问：哪种检测类型在尿液分析市场中占据主导地位？

A: Biochemical tests held a leading position by test type in 2025, driven by routine strip-based screening.

A：2025年，按检测类型划分，生化检测占据主导地位，这主要得益于基于试纸条的常规筛查。

Q: Which region leads the urinalysis market?

问：哪个地区在尿液分析市场中处于领先地位？

A: North America held a leading regional position in 2025, while Asia Pacific is the fastest-growing region.

A：2025年，北美地区占据领先地位，而亚太地区是增长最快的地区。

Q: Who are the top players in the urinalysis market?

问：尿液分析市场的主要参与者有哪些？

A: Leading companies include Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Sysmex Corporation, Beckman Coulter, Inc. and ARKRAY, Inc.

A：领先企业包括西门子医疗股份公司、罗氏诊断公司、希森美康集团、贝克曼库尔特公司和爱科来株式会社。

Q: How consolidated is the urinalysis market?

问：尿液分析市场的集中度如何？

A: It is moderately consolidated at the advanced instrument level and fragmented across reagent strips, consumables, point-of-care devices and regional manufacturers.

A：在高端仪器层面，市场呈现中度集中态势；而在试剂条、耗材、即时检测设备以及区域性制造商方面，市场则较为分散。

As laboratories look for faster, more consistent workflows and clinicians push for earlier kidney disease detection, urinalysis is moving beyond a simple dipstick test. Suppliers that pair reliable consumables with automated, connected and affordable systems are best placed to capture the next wave of demand..

随着实验室寻求更快速、更一致的工作流程，以及临床医生推动更早发现肾脏疾病，尿液分析正超越简单的试纸条检测。将可靠的耗材与自动化、互联且经济实惠的系统相结合的供应商，最有望抓住下一波需求浪潮。

Expert Profile | Mayur Jain, Wissen Research

专家档案 | Mayur Jain，Wissen Research

Mayur Jain is a Research Expert at Wissen Research with multidomain expertise with more than 12+ years of experience in market research industry.

马尤尔·贾因是Wissen Research的研究专家，拥有12年以上的市场研究行业经验，具备多领域专业知识。

Email:

电子邮件：

[email protected]

LinkedIn:

领英：

https://www.linkedin.com/in/mayur-jain-0190542a/

About Wissen Research

关于Wissen研究

Wissen Research is a global market intelligence and consulting firm specializing in healthcare, life sciences, technology, and emerging industries. The company provides data-driven insights, strategic market analysis, and industry forecasts to help organizations make informed business decisions and identify new growth opportunities across global markets.

Wissen Research 是一家全球市场情报与咨询公司，专注于医疗保健、生命科学、技术和新兴行业领域。该公司提供数据驱动的洞察、战略市场分析和行业预测，帮助组织做出明智的商业决策，并在全球市场中识别新的增长机会。

Company Contact:

公司联系人：

Wissen Research LLC,

Wissen Research 有限责任公司，

Gould St, Ste R,

古尔德街，R室，

Sheridan, WY 82801,

怀俄明州谢里登，邮编 82801

Phone: (+1) 510 240 9853

电话：(+1) 510 240 9853

Email: